On December 3, 2024, Fosun Pharma announced that the loan term of its controlling subsidiary Foyun Health will be extended by 12 months to December 4, 2025. The total amount of the extension involves a loan of 65.5 million yuan, provided by Fosun Health, Ningbo Foji, and Fosun High Technology according to their respective shareholding ratios. The loan portions of Fosun Health and Ningbo Foji were within the approved limit of the shareholders' meeting in 2023, while the loan portion of Fosun High Technology constituted related party financial assistance according to the Shanghai Stock Exchange Listing Rules but did not meet the board's review standards. Foyun Health was established in May 2021, mainly engaged in the research and sales of health management products and services. According to...Show More

On December 3, 2024, Fosun Pharma announced that the loan term of its controlling subsidiary Foyun Health will be extended by 12 months to December 4, 2025. The total amount of the extension involves a loan of 65.5 million yuan, provided by Fosun Health, Ningbo Foji, and Fosun High Technology according to their respective shareholding ratios. The loan portions of Fosun Health and Ningbo Foji were within the approved limit of the shareholders' meeting in 2023, while the loan portion of Fosun High Technology constituted related party financial assistance according to the Shanghai Stock Exchange Listing Rules but did not meet the board's review standards. Foyun Health was established in May 2021, mainly engaged in the research and sales of health management products and services. According to its management report, as of October 31, 2024, Foyun Health's total assets were 8.56 million yuan, total liabilities were 94.26 million yuan, and net profit was -11.17 million yuan. The loan extension is to meet Foyun Health's daily operational needs and is expected to have no significant impact on the daily operations of the Fosun Pharma Group. Fosun Pharma stated that they will continue to closely monitor the financial situation of Foyun Health, strengthen risk control and repayment management to ensure the security of the group's funds. The loan extension does not require separate approval from the board of directors or shareholders' meeting, in line with the company's internal management system and relevant regulatory requirements.